GX-H9: Phase I data

Top-line data from a double-blind, placebo-controlled Phase I trial in 32 healthy volunteers showed that single doses of 0.2, 0.4, 0.8 and 1.6 mg/kg subcutaneous GX-H9 were well tolerated and dose-dep...